By the direct Fick or the indocyanine-green or both, methods and by renal clearance of inulin and para-aminohippurate (PAH), simultaneous cardiorenal hemodynamic observations were made before and during isoproterenol infusion (0.9-2.6 jug/ min) into three patients without, and 10 patients with, heart disease. Although a consistent increase in cardiac output (11 to 147%) was noted in all patients, no significant change in glomerular filtration rate or renal blood flow was observed. The percentage of the cardiac output delivered to the kidney during drug infusion decreased in all subjects. The renal extraction of PAH, measured in three patients, was not changed during isoproterenol administration. The infusion of isoproterenol to normovolemic and hypervolemic dogs (10 dogs) increased the cardiac output in all animals but produced no significant change in glomerular filtration rate or renal blood flow. Because the renal blood flow is not affected by the increased cardiac output produced by isoproterenol, the data suggest that there is either a weak or an absent beta-receptor response in the kidney in the dog and man.
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Hypervolemia Dopamine vascular response.9-11 The reported renal vascular response in dog to intravenous administration of isoproterenol has been variable.'0' 12, 13 This paper presents observations on the acute intravenous administration of isoproterenol on the cardiorenal hemodynamics in man, with and without heart disease.
Methods
The effect of acute intravenous administration of isoproterenol on cardiorenal hemodynamics was studied in 13 patients: three noncardiac subjects and 10 patients with heart disease. Two of the three patients without heart disease were hospitalized with pulmonary tuberculosis; the third, had multiple subjective complaints but no objective evidence of heart disease. A full diagnostic right and left heart catheterization was performed. Of the 10 patients with heart disease, four were never in cardiac failure: one had idiopathic hyper-ISOPROTERENOL AND CARDIORENAL HEMODYNAMICS myocardial disease. The remaining six were all maintained on digitalis, and diuretic therapy was given as indicated for cardiac failure. Three had mitral valve disease, secondary to rheumatic heart disease; two had primary myocardial disease; and one had mitral insufficiency of undetermined etiology.
Complete Table 1 summarizes the cardiac output and renal blood flow data. The three noncardiac subjects and the 10 patients with heart disease all had significant increase in cardiac output (11 to 147%) . This increase occurred regardless of the severity of the heart disease. In three patients the heart rate remained unchanged during isoproterenol administration and, therefore, the increase in cardiac output was due solely to stroke volume. In three patients, stroke volume remained unchanged with the increase in heart 
Il.
C. .. renal plasma flow that were not significant (+4 to 9%). All other patients had no change or a decrease in renal flow. The changes in glomerular filtration rates paralleled those for the renal blood flow. The effect of isoproterenol on blood pressure, ventricular end-diastolic pressures, and peripheral and pulmonary resistances is as reported by others and is not within the scope of this paper. 3' 6 Urinary excretion of electrolytes during isoproterenol infusion was unchanged compared with control values, except for W.C. and M.B.M., whose isoproterenol was diluted in 0.9% NaCl and who had an increase in sodium and chloride excretion during the infusion period (table 2) .
The extraction of PAH was not significantly altered during the experimental period (table 3).
In the two patients whose cardiac and renal dynamics were measured after isoproterenol infusion was discontinued, the cardiac outputs decreased to control values. terenol in three normal and seven of eight cardiac subjects, with and without chronic heart failure, so studied, demonstrated either no change or a decrease in glomerular filtration rate and renal blood flow, despite an increase in cardiac output in all subjects. In only one patient with chronic heart failure, who had over 100% increase in cardiac output, was there an increase in renal blood flow greater than 10%. The fraction of the cardiac output delivered to the kidney decreased in all subjects during drug infusion. The lack of reaction of the renal vascular resistance in normotensive man to isoproterenol suggests the following: that (a) there are no betareceptor sites in the human kidney, or (b) if proterenol does not alter the effective renal blood flow in the intact dog. From these studies and those reviewed, the renal vascular resistances in normotensive dog and man are not significantly altered by betaadrenotropic stimulation.
The renal extractions of PAH in three human subjects were unchanged during drug infusion, indicating that total renal plasma flow, as well as the effective renal plasma flow, is not changed by isoproterenol administration.
On the administration of isoproterenol in the vasoconstricted, low cardiac output states observed during the postoperative period after open heart surgery, urine flow is invariably increased as the clinical condition improves and the blood pressure increases. One might infer an increase in renal blood flow at this time. Objective measurements are not available to evaluate the effect of isoproterenol on renal blood flow during these shocklike states. However, in myocardial shock, Smith and associates25 noted an increase in urine output for only three of 11 patients during isoproterenol infusion, whereas MacLean and associates26 noted the increase in urine flow associated with this drug's administration in coronary shock. Weil and Shubin,27 in their review of the subject, made no mention of the effect of isoproterenol on renal blood flow in shock.
